Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00301756 · FLOW

Participant flow

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors · Source last updated 2018-08-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Treatment (Belinostat / Enzyme Inhibitor Therapy)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        32
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        32
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Treatment (Belinostat / Enzyme Inhibitor Therapy)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        32
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        32
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice